As different growth factor receptors share common downstream signaling pathways, and inhibition of one growth factor receptor may upregulate other growth factor receptors, blockade of a common upstream regulatory mechanism of growth factor receptors has potential as a potent anti-cancer therapy and may enable resistance against anti-EGFR therapy to be overcome [35, 36]. The gene discussed is EGFR; the disease is cancer.